Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Eun-Shin | - |
dc.contributor.author | Han, Wonshik | - |
dc.contributor.author | Kim, Min Kyoon | - |
dc.contributor.author | Kim, Jongjin | - |
dc.contributor.author | Yoo, Tae-Kyung | - |
dc.contributor.author | Lee, Moo Hyun | - |
dc.contributor.author | Lee, Kyung Hun | - |
dc.contributor.author | Kim, Tae Yong | - |
dc.contributor.author | Moon, Hyeong-Gon | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Noh, Dong-Young | - |
dc.contributor.author | Lee, Eun Sook | - |
dc.date.accessioned | 2024-01-09T14:12:08Z | - |
dc.date.available | 2024-01-09T14:12:08Z | - |
dc.date.issued | 2016-07 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/70405 | - |
dc.description.abstract | Background: Recent large trials have shown the survival benefits of 10-year use of tamoxifen by reducing late recurrence compared with 5-year therapy in estrogen receptor(ER)-positive breast cancer. We tried to identify clinical factors associated with the late recurrence. Methods: We reviewed our database of ER-positive patients who had received operations between 1996 and 2006 in two institutions. We selected 444 who had completed 5-year tamoxifen and were disease-free up to 10 years after the operation. Patients who had received aromatase inhibitors with any regimens were excluded. As a late recurrence group, 139 patients were identified who had completed 5-year tamoxifen, but had recurrence afterwards. Among them, 61 had local/contralateral breast recurrence and 78 had distant metastasis. The median follow-up was 9.7 years. Clinicopathological factors at the time of initial operation, such as age, menopausal status, progesterone receptor expression, HER2 status, tumor grade and Ki-67, were compared between the disease-free group and the late recurrence group. Results: In a univariate analysis, tumor size (>2 cm), lymph node metastasis and high histologic grade were significantly associated with late recurrences (p < 0.05). In a multivariate analysis, only axillary lymph node metastasis was significant (p < 0.001). Late distant metastasis was significantly associated with tumor size and axillary lymph node metastasis (p = 0.038, p < 0.001, respectively). Late local/contralateral breast recurrence was associated with axillary lymph node metastasis (p = 0.042). Conclusions: Our data showed axillary lymph node metastasis at initial operation was the only risk factor of late recurrence after completion of tamoxifen for 5 years. Our results can be helpful in making decisions to use extended tamoxifen beyond 5 years. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BMC | - |
dc.title | Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.1186/s12885-016-2423-x | - |
dc.identifier.bibliographicCitation | BMC CANCER, v.16 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000379207300001 | - |
dc.identifier.scopusid | 2-s2.0-84991745926 | - |
dc.citation.title | BMC CANCER | - |
dc.citation.volume | 16 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Estrogen receptor (ER)-positive breast cancer | - |
dc.subject.keywordAuthor | Late recurrence | - |
dc.subject.keywordAuthor | Extended tamoxifen | - |
dc.subject.keywordPlus | LATE DISTANT RECURRENCE | - |
dc.subject.keywordPlus | PROGNOSTIC INFORMATION | - |
dc.subject.keywordPlus | POSTMENOPAUSAL WOMEN | - |
dc.subject.keywordPlus | ENDOCRINE THERAPY | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | UPDATED FINDINGS | - |
dc.subject.keywordPlus | PAM50 RISK | - |
dc.subject.keywordPlus | FOLLOW-UP | - |
dc.subject.keywordPlus | LETROZOLE | - |
dc.subject.keywordPlus | SCORE | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.